HUM vs ROIV
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
HUM shows bearish fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Concerns include weak profitability or high valuation.
ROIV presents a stark divergence between deterministic financial health and market sentiment. The Piotroski F-Score of 1/9 indicates severe fundamental weakness, compounded by an absurd Price/Sales ratio of 1604.01 and heavy insider selling totaling $175.18M. However, the company maintains an extraordinary liquidity position with a Current Ratio of 30.66 and negligible debt (Debt/Equity 0.02), suggesting it is a well-funded biotech 'cash shell' betting on its pipeline. While analysts maintain a 'strong_buy' rating with a target of $35.67, the fundamental data is overwhelmingly bearish.
Compare Another Pair
Related Comparisons
HUM vs ROIV: Head-to-Head Comparison
This page compares Humana Inc. (HUM) and Roivant Sciences Ltd. (ROIV) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.